Tag:
Transgene
Latest Headlines
Latest Headlines
Transgene is shedding 120 jobs to save cash and get its pipeline moving
French biotech Transgene is planning to slash its payroll and redouble its focus on clinical development, moving on from a costly snub at the hands of Novartis.
Britain fearful of Pfizer future, UCB on the hunt for antibody partners, Novartis snubs Transgene
In this week's EuroBiotech Report, British trade unions and politicians are calling for guarantees that Pfizer won't perform its now-traditional post-takeover cuts in the event it succeeds in its pursuit of AstraZeneca, Ireland is worried that its business-friendly taxes aren't attracting the sort of job-creating biopharma companies it wants, and more.
Transgene takes a hit as Novartis shreds $800M option deal
France's Transgene took a hit this morning after the biotech announced that Novartis had decided to pass on its option for the therapeutic cancer vaccine TG4010. But the CEO says he's laying the groundwork for a late-stage study, confident that he can find another partner.
Transgene, Jennerex ponder fate of tumor-fighting virus after PhIIb failure
Transgene expected the European commercialization rights to Jennerex's oncolytic virus immunotherapy JX-594 to eventually be worth more than $1 billion. But a Phase IIb trial for the drug has now failed the primary endpoint of overall survival in advanced liver cancer patients.
Sanofi beefs up CMO game with Transgene deal
France's Sanofi is expanding its contract manufacturing capabilities, teaming up with Transgene to spend $13 million on a new CMO platform.
French biotech rapidly stuck on losing side of hep C revolution
French biotech Transgene has watched partnership prospects vanish for its experimental vaccine against hepatitis C over the past year, as all-oral regimens against the liver-damaging disease have quickly taken over as the future therapy of choice.
PsiOxus launches human tests of cancer vaccine
PsiOxus Therapeutics began human clinical trials of its cancer vaccine ColoAd1--a highly potent anti-cancer therapeutic that destroys tumor cells at minute concentrations.
Inovio, Transgene and ChronTech enter HepC pact
Using a variation of the typical booster shot vaccination process, Inovio Pharmaceuticals, Transgene and ChronTech Pharma have joined together for a Phase I study of a therapeutic hepatitis C
R&D; realignment prompts Roche to dump Transgene HPV pact
Roche has decided to exit its pact to develop and commercialize TG4001 (RG3484), a therapeutic vaccine to treat high grade cervical intraepithelial neoplasia lesions caused by human papillomavirus
Roche pulls out of Transgene vaccine pact
Roche has decided to exit its pact to develop and commercialize TG4001 (RG3484), a therapeutic vaccine to treat high grade cervical intraepithelial neoplasia lesions caused by human papillomavirus
